December

Temporary Rule: Extension of Temporary Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (PDF) (December 30, 2024)

Proposed Rule: Placement of 4-Chloromethcathinone in Schedule I (PDF) (December 30, 2024)

Proposed Rule: Placement of Seven Specific Fentanyl-Related Substances in Schedule I (PDF) (December 30, 2024)

Soroosh Armandi, D.O.; Decision and Order (PDF) (December 30, 2024)

Maria Dewitt, N.P.; Decision and Order (PDF) (December 30, 2024)

Robert Esser, D.D.S.; Decision and Order (PDF) (December 30, 2024)

Matthew Okeke, M.D.; Decision and Order (PDF) (December 30, 2024)

Kevin Petersen, M.D.; Decision and Order (PDF) (December 30, 2024)

Jason Lee Ray, PA-C; Decision and Order (PDF) (December 30, 2024)

Shiva Akula, M.D.; Decision and Order (PDF) (December 30, 2024)

Samreen Riaz, D.D.S.; Decision and Order (PDF) (December 30, 2024)

Jeffrey W. Young, Jr., N.P.; Decision and Order (PDF) (December 30, 2024)

Irvine Labs Inc. (PDF) (December 30, 2024)

Siegfried USA, LLC (PDF) (December 30, 2024)

Curia New York, Inc. (PDF) (December 30, 2024)

Leading Pharma LLC (PDF) (December 18, 2024)

Final Order: Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024 (PDF) (December 17, 2024)

Final Order: Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025 (PDF) (December 17, 2024)

National Center for Natural Products Research (PDF) (December 13, 2024)

Groff NA Hemplex LLC (PDF) (December 13, 2024)

30-Day Notice: Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A (PDF) (December 12, 2024)

Kinetochem LLC (PDF) (December 6, 2024)

Navinta LLC (PDF) (December 6, 2024)

Organic Standards Solutions International, LLC (PDF) (December 6, 2024)

Noramco (PDF) (December 6, 2024)

Curia Wisconsin, Inc. (PDF) (November 29, 2024)

Cambrex Charles City (PDF) (November 29, 2024)

November

60-Day Notice: Recordkeeping for Electronic Prescriptions for Controlled Substances (PDF) (November 26, 2024)

Experic LLC (PDF) (November 26, 2024)

Cayman Chemical Company (PDF) (November 26, 2024)

Organix Chemistry Solutions, LLC (PDF) (November 26, 2024)

National Center for Natural Products Research (PDF) (November 26, 2024)

Isosciences, LLC (PDF) (November 26, 2024)

Temporary Rule: Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (PDF) (November 19, 2024)

October

Proposed Rule: Possible Control of Phenethyl Bromide as a List I Chemical (PDF) (October 28, 2024)

Final Rule: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I (PDF) (October 25, 2024)

30-Day Notice: Exempt Chemical Preparations Under the Controlled Substance Act (PDF) (October 25, 2024)

David Carlos Rodriguez, M.D.; Decision and Order (PDF) (October 23, 2024)

BRX Pharmacy; Decision and Order (PDF) (October 23, 2024)

Itani Family Pharmacy, PLC; Decision And Order (PDF) (October 23, 2024)

Dale Fitzpatrick, M.D.; Decision and Order (PDF) (October 23, 2024)

Irvine Labs, Inc. (PDF) (October 23, 2024)

Mylan Technologies Inc. (PDF) (October 23, 2024)

Halo Pharmaceutical Inc. (PDF) (October 23, 2024)

Irvine Labs, Inc. (PDF) (October 23, 2024)

Final Rule: Placement of Ethylphenidate in Schedule I (PDF) (October 22, 2024)

Neeraj B. Shah, M.D.; Decision and Order (PDF) (October 21, 2024)

Michael Berman, D.O.; Decision and Order (PDF) (October 11, 2024)

William J. Mack, M.D.; Decision and Order (PDF) (October 11, 2024)

Robert P. Hansen, M.D.; Decision and Order (PDF) (October 11, 2024)

Janet S. Pettyjohn, D.O.; Decision and Order (PDF) (October 11, 2024)

Salman Akbar, M.D.; Decision and Order (PDF) (October 10, 2024)

Midtown Specialty RX; Decision and Order (PDF) (October 10, 2024)

Halowells Pharmacy; Decision and Order (PDF) (October 10, 2024)

Merry Alice Troupe, N.P.; Decision and Order (PDF) (October 8, 2024)

60-Day Notice: Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A (PDF) (October 7, 2024)

Curia Wisconsin, Inc. (PDF) (October 1, 2024)

Fresenius Kabi USA, LLC (PDF) (October 1, 2024)

September

Theodore S. Wright Jr., M.D.; Decision and Order (PDF) (September 27, 2024)

Wagner Gervais, P.A.; Decision and Order (PDF) (September 27, 2024)

Lawrence Rudolph, D.M.D.; Decision and Order (PDF) (September 27, 2024)

Adam L. Larson, M.D.; Decision and Order (PDF) (September 27, 2024)

Michael Fletcher, M.D.; Decision and Order (PDF) (September 27, 2024)

Charles Sangmoah, P.A.; Decision and Order (PDF) (September 27, 2024)

Curium US LLC (PDF) (September 25, 2024)

Notice with Request for Comments: Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024 (PDF) (September 25, 2024)

Notice with Request for Comments: Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025 (PDF) (September 25, 2024)

Proposed Amendment: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (PDF) (September 17, 2024)

George D. Gowder, III, M.D.; Decision and Order (PDF) (September 17, 2024)

Chemtos, LLC (PDF) (September 17, 2024)

Eli-Elsohly Laboratories (PDF) (September 17, 2024)

Mary A. Vreeke, M.D.; Decision and Order (PDF) (September 16, 2024)

Awesome Care Pharmacy, Inc.; Decision and Order (PDF) (September 16, 2024)

Purisys, LLC (PDF) (September 16, 2024)

Bright Green Corporation (PDF) (September 6, 2024)

Biopharmaceutical Research Company (PDF) (September 6, 2024)

Cambridge Isotope Laboratories, Inc. (PDF) (September 6, 2024)

Final Order: Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2024 (PDF) (September 5, 2024)

Samirkumar Shah, M.D.; Decision and Order (PDF) (September 4, 2024)

Chattem Chemicals (PDF) (September 4, 2024)

Bright Green Corporation (PDF) (September 4, 2024)

Continuus Pharmaceuticals (PDF) (September 4, 2024)

Catalent CTS, LLC (PDF) (September 4, 2024)

Benuvia Operations, LLC (PDF) (September 4, 2024)

Indivior Inc. (PDF) (September 4, 2024)

Amneal Complex Products Research LLC (PDF) (September 4, 2024)

Chattem Chemicals, Inc. (PDF) (September 4, 2024)

Biopharmaceutical Research Company (PDF) (September 4, 2024)

Cambridge Isotope Laboratories, Inc. (PDF) (September 4, 2024)

Fisher Clinical Services, Inc. (PDF) (September 4, 2024)

Caligor Coghlan Pharma Services (PDF) (September 4, 2024)

Cambrex High Point, Inc (PDF) (September 4, 2024)

Stephen McCarthy, P.A.; Decision and Order (PDF) (September 3, 2024)

August

Proposed Rule: Rescheduling of Marijuana (PDF) (August 29, 2024)

60-Day Notice: Exempt Chemical Preparations Under the Controlled Substance Act (PDF) (August 23, 2024)

Final Rule: Placement of Zuranolone in Schedule IV (PDF) (August 14, 2024)

Robert Rowen, M.D.; Decision and Order (PDF) (August 14, 2024)

Irene Kimura, M.D.; Decision and Order (PDF) (August 14, 2024)

Thomas M. Fausset, O.D.; Decision and Order (PDF) (August 14, 2024)

Michael L. Brodie, M.D.; Decision and Order (PDF) (August 14, 2024)

Stephen Matthews, M.D.; Decision and Order (PDF) (August 9, 2024)

Experic LLC (PDF) (August 8, 2024)

Cambrex High Point, Inc. (PDF) (August 8, 2024)

AMPAC Fine Chemicals, LLC (PDF) (August 8, 2024)

Cambrex Charles City (PDF) (August 8, 2024)

Catalent Greenville, Inc. (PDF) (August 8, 2024)

Benuvia Operations, LLC (PDF) (August 8, 2024)

VICI Health Sciences, LLC (PDF) (August 8, 2024)

Cerilliant Corporation (PDF) (August 8, 2024)